KSCCM
Search
- Page Path
- HOME > Search
Review Article
- Basic science and research
- Review of remimazolam and sedatives in the intensive care unit
- Hey-Ran Choi, In-Ae Song
- Acute Crit Care. 2022;37(2):151-158. Published online May 30, 2022
- DOI: https://doi.org/10.4266/acc.2022.00619
- 6,867 View
- 389 Download
- 8 Web of Science
- 10 Crossref
-
Abstract
PDF - Remimazolam is a novel intravenous ultra-short acting benzodiazepine that has the potential of being a safe and effective new sedative for use in intensive care unit (ICU) settings. Because remimazolam metabolizes rapidly by being hydrolyzed to an inactive metabolite (CNS 7054) through non-specific tissue esterase activity, specific dosing adjustment for older adults and for patients with renal or hepatic impairment patients (except for those with severe hepatic impairment) is not required. In addition, research has shown that remimazolam may be reversed by administration of flumazenil, as its half time was sufficiently short compared to flumazenil. It shows a lower incidence of cardiorespiratory depression, less injection pain, and no fatal complications such as propofol infusion syndrome and malignant hyperthermia of inhalational anesthetics. Future studies to study the suitability of remimazolam for managing the sedation of ICU patients who need sedation for a long time over several days is required.
-
Citations
Citations to this article as recorded by
- The degree of respiratory depression according to the effect-site concentration in remimazolam target-controlled infusion
Soo Jung Park, Sang Kee Min, Gyubin Choi, Ji Eun Kim, Ha Yeon Kim
European Journal of Anaesthesiology.2024; 41(10): 728. CrossRef - “The Psychiatric Domain of Post-Intensive Care Syndrome: A Review for the Intensivist”
Allison Rhodes, Christopher Wilson, Dimitar Zelenkov, Kathryne Adams, Janelle O. Poyant, Xuan Han, Anthony Faugno, Cristina Montalvo
Journal of Intensive Care Medicine.2024;[Epub] CrossRef - Remimazolam Anesthesia for a Pediatric Patient With Glutaric Aciduria Type I: A Case Report
Tomoko Tsuruno, Hiroki Tateiwa, Yuki Hashimoto, Yoshifumi Katsumata, Takashi Kawano
Cureus.2024;[Epub] CrossRef - Remimazolam – Update zu Grundlagen und klinischem Potenzial
Vera Scheckenbach, Berthold Drexler
Die Anaesthesiologie.2024; 73(9): 617. CrossRef - Con: Remimazolam: The New Miracle Cure for Critically Ill Patients
Rayssa Becerra Orjuela, Juan G. Ripoll
Journal of Cardiothoracic and Vascular Anesthesia.2024;[Epub] CrossRef - Optimizing Pediatric Sedation: Evaluating Remimazolam and Dexmedetomidine for Safety and Efficacy in Clinical Practice
Vera Scheckenbach, Frank Fideler
Pediatric Drugs.2024;[Epub] CrossRef - Remimazolam: A New Ingress in Cardiac Surgical Intensive Care Unit
Minati Choudhury, Poonam Malhotra Kapoor
Journal of Cardiac Critical Care TSS.2023; 7: 133. CrossRef - Safety and efficacy of remimazolam tosilate combined with low-dose fentanyl for procedural sedation in obese patients undergoing gastroscopy: study protocol for a single-centre, double-blind, randomised controlled trial
Lijuan Yan, Xiao Wang, Zhenyi Chen, Ningning Wu, Hao Li, Bin Yang
BMJ Open.2023; 13(12): e079095. CrossRef - Remimazolam: An Updated Review of a New Sedative and Anaesthetic
Qinxue Hu, Xing Liu, Chengli Wen, Duo Li, Xianying Lei
Drug Design, Development and Therapy.2022; Volume 16: 3957. CrossRef - National analysis of applied sedation in critical care patients
Grace Pamela López Pérez , Melani Dayana Carrera Casa , Gissela Lizbeth Amancha Moyulema , Yadira Nathaly Chicaiza Quilligana , Ana Belén Guamán Tacuri , Joselyn Mireya Iza Arias
Salud, Ciencia y Tecnología.2022; 2: 234. CrossRef
- The degree of respiratory depression according to the effect-site concentration in remimazolam target-controlled infusion
First
Prev
